Employer and payer contracting: Sponsors are expected to test virtual-first models that combine access, coaching and utilization reporting
The Ethical Questions GLP-1 drugs represent a genuine medical breakthrough for many people struggling with obesity and metabolic disease
This increase in clinical use can be attributed in part to a number of favorable qualities including: 1) robust glucose-lowering efficacy
For example, Ozempic is typically administered as a once-weekly injection and comes in pre-set dosages (0.25 mg, 0.5 mg, 1 mg, or 2 mg per week), whereas compounded versions may be customized to different concentrations
Because of the close relationship between risk factors in human metabolism and the expression of GLP-1R in the musculoskeletal system, GLP-1RAs may have great potential in the treatment of many diseases of the musculoskeletal system
Equally effective as GLP-1 treatments